Profile data is unavailable for this security.
About the company
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
- Revenue in USD (TTM)65.18bn
- Net income in USD20.64bn
- Incorporated1901
- Employees47.00k
- LocationEli Lilly and CoLilly Corporate Ctr, Drop Code 1094INDIANAPOLIS 46285United StatesUSA
- Phone+1 (317) 276-2000
- Fax+1 (317) 276-3492
- Websitehttps://www.lilly.com/
Mergers & acquisitions
| Acquired company | LLY:NYQ since announced | Transaction value |
|---|---|---|
| Ventyx Biosciences Inc | -0.55% | 1.01bn |
| Adverum Biotechnologies Inc | 28.88% | 274.32m |
| Verve Therapeutics Inc | 31.03% | 1.25bn |
| SiteOne Therapeutics Inc | 48.26% | 1.00bn |
